Formulation and Drug Delivery

CordenPharma and Certest Team Up on Ionizable Lipids to Develop LNP Formulations

June 12, 2024

CordenPharma has partnered with Spain-based Certest to develop ionizable lipids for LNP formulations.

Determination of Shelf-Life from Stability Data: From Replicates or from Averages?

June 11, 2024

A statistical analysis for determining an expiration date can be applied to replicates or their corresponding averages as suggested in industry guidelines.

Using Advanced Algorithms to Solve Formulation Challenges

June 09, 2024

Artificial intelligence and machine learning can help overcome poor solubility and bioavailability.

Diversifying the Supply of Raw Materials

June 08, 2024

The final drug product relies on the quality and reliability of the raw materials used in its production.

Reviewing the Importance of Biosimilarity and Interchangeability

June 06, 2024

Biosimilar analytical assessments focus on demonstrating biosimilarity and interchangeability with the reference biologic.

Finding a More Optimal Way for ATMPs (BIO 2024)

June 04, 2024

Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.

Exploring the Potential of mRNA (BIO 2024)

June 04, 2024

Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.

Seeking Excellence with CRISPR (BIO 2024)

June 04, 2024

Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.

Rapid Sterility Methods for CAR T-cell Therapies

May 30, 2024

A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.

FDA Approves Interchangeable Biosimilar to Soliris

May 30, 2024

Bkemv (eculizumab-aeeb) is the first interchangeable biosimilar to Soliris (eculizumab) to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.